Ortin Laboratories Ltd
Incorporated in 1986, Ortin Laboratories Ltd is engaged in the manufacturing and trading of Pharmaceuticals, Drugs and Intermediates.
- Market Cap ₹ 16.3 Cr.
- Current Price ₹ 20.1
- High / Low ₹ 26.4 / 16.2
- Stock P/E
- Book Value ₹ 3.47
- Dividend Yield 0.00 %
- ROCE -60.2 %
- ROE -118 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 5.80 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -57.7% over past five years.
- Promoter holding is low: 1.23%
- Company has a low return on equity of -29.4% over last 3 years.
- Company has high debtors of 283 days.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -14.4%
- Working capital days have increased from 190 days to 314 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
74.74 | 67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.28 | 0.92 | |
68.17 | 60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 8.65 | 7.57 | |
Operating Profit | 6.57 | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -6.37 | -6.65 |
OPM % | 8.79% | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -279.39% | -722.83% |
0.24 | 0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | 0.00 | 0.00 | |
Interest | 3.55 | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 | 0.37 |
Depreciation | 1.40 | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 | 0.17 |
Profit before tax | 1.86 | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 | -7.19 |
Tax % | 41.40% | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% | |
1.09 | 1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 | -8.15 | |
EPS in Rs | 0.64 | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 | -10.02 |
Dividend Payout % | 38.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -29% |
5 Years: | -58% |
3 Years: | -35% |
TTM: | -82% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2190% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | -12% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | -2% |
5 Years: | -11% |
3 Years: | -29% |
Last Year: | -118% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 |
Reserves | 3.84 | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 |
17.92 | 18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 | |
34.80 | 31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 1.97 | |
Total Liabilities | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
24.77 | 23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 |
Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
48.70 | 48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.58 | |
Total Assets | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1.66 | -1.76 | -1.38 | 0.52 | 1.94 | 1.56 | 6.52 | 3.30 | 18.03 | 2.15 | -0.25 | -3.67 | |
-2.08 | -0.02 | 0.22 | -0.86 | -1.26 | -0.90 | -3.27 | -3.09 | 0.07 | -0.13 | 0.01 | 11.50 | |
4.70 | 0.97 | 1.73 | 0.27 | -0.82 | 0.07 | -2.89 | -1.33 | -9.86 | -0.47 | 0.90 | -3.49 | |
Net Cash Flow | 0.96 | -0.81 | 0.58 | -0.07 | -0.14 | 0.73 | 0.37 | -1.12 | 8.25 | 1.55 | 0.66 | 4.34 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 134.10 | 116.69 | 103.77 | 53.13 | 90.35 | 100.15 | 82.43 | 68.71 | 174.90 | 143.69 | 208.05 | 283.36 |
Inventory Days | 102.80 | 162.92 | 192.30 | 148.72 | 158.21 | 152.21 | 100.07 | 117.80 | 169.10 | 136.29 | 279.94 | 4.92 |
Days Payable | 199.45 | 197.95 | 151.09 | 24.82 | 108.10 | 143.09 | 145.12 | 155.80 | 123.82 | 61.88 | 166.89 | 7.87 |
Cash Conversion Cycle | 37.45 | 81.66 | 144.97 | 177.04 | 140.45 | 109.28 | 37.38 | 30.70 | 220.17 | 218.10 | 321.10 | 280.40 |
Working Capital Days | 56.94 | 86.07 | 118.60 | 104.81 | 126.92 | 108.68 | 48.94 | 38.38 | 158.79 | 86.93 | 168.51 | 313.77 |
ROCE % | 14.90% | 13.08% | 12.07% | 10.92% | 9.57% | 9.44% | 11.77% | 8.94% | 3.24% | 1.58% | 1.80% | -60.19% |
Documents
Announcements
- Board Meeting Outcome for Out Come Of BM 13 Aug
- Un-Audited Financial Results For The Quarter Ended 30-06-2024 13 Aug
- Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter Ended 30.06.2024 6 Aug
- Postponement Of Board Meeting Scheduled To Be Held On 31.07.2024 31 Jul
- Board Meeting Intimation for Board Meeting To Be Held On 31.07.2024 24 Jul
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:
a) Formulations:[1] Anti Diabetics, Anti Allergics, Anti Anginal & Cardio Vascular, Sedatives & Tranquillizers, Analgesics & Antipyretics Anti Helmenthetics, Anti-fungal, Anti Biotics-Quinolones, Anti Biotic-Penicillin, Chemo Therapeutics, Cephalosporins, Macrolides, Anti-ulcerants & Antacids, Anti-spasmodic, Calcium preparations, Iron preparations, Gynec, Anti -Arthritic Drugs, Protein supplements, Enzymes, Vitamins, Psychiatry, Appetizers, Anti-Retroviral
b) API Intermediates:[2] Anti retro viral, Anti Diabetics, Antifungal, Antacids & Anti ulcerant, Analgesics & Antipyretics, Anti - Biotic, Anti malarial, Fine chemicals, Grignard & alkali metal products
c) Merchant Export Trading:[3]
Company supplies pharmaceutical formulations comprising tablets, capsules, liquid orals, ear
drops, nasal drops, ointments, liquid injections, sterile dry powder injections, pharmaceutical veterinary tablets, dry syrups, sterile powder.